Tyra Biosciences Inc (TYRA)

$28.81 +0.04 (0.14%)
Market Cap 1.54B
Revenue (ttm) 0.00
Net Income (ttm) -86.48M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 440,700
Avg Vol 517,850
Day's Range N/A - N/A
Shares Out 53.37M
Stochastic %K 67%
Beta 1.07
Analysts Strong Sell
Price Target $33.57

Company Profile

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in clinical trials for the treatment of patients with...

Industry: Biotechnology
Sector: Healthcare
Phone: 619 728 4760
Website: tyra.bio
Address:
2656 State Street, Carlsbad, United States
GreenPhantom
GreenPhantom Jan. 5 at 1:34 AM
$TYRA Tyra's pipeline is focused on precision medicine and developing drugs that target specific cancer mutations.
0 · Reply
GreenPhantom
GreenPhantom Jan. 5 at 1:33 AM
$TYRA
0 · Reply
GreenPhantom
GreenPhantom Jan. 5 at 1:32 AM
$TYRA Strong Scientific Foundation and Experienced Management
0 · Reply
TradeBalanceT
TradeBalanceT Dec. 25 at 1:11 PM
$TYRA Capital stewardship is becoming the defining attribute for how this story is priced. The market is increasingly intolerant of delays that stretch credibility. Without proof, upside scenarios remain hypothetical and heavily discounted. The market will respond to evidence, not speculation.
0 · Reply
anachartanalyst
anachartanalyst Dec. 16 at 8:02 PM
$TYRA https://anachart.com/wp-content/uploads/ana_temp/1765915319_soc-img.jpg
0 · Reply
JarvisFlow
JarvisFlow Dec. 16 at 12:36 PM
Wedbush updates rating for Tyra Biosciences ( $TYRA ) to Outperform, target set at 30 → 37.
0 · Reply
Quantumup
Quantumup Dec. 16 at 12:14 PM
Wedbush Added $TYRA to their Best Idea List while⬆️the PT to $37 from $30 and reiterating at an Outperform rating. $URGN $JNJ $BBIO $ASND SNY BMRN Wedbush said—We are adding TYRA to the Wedbush Best Ideas List ahead of a busy 2026, with data from two ongoing Ph 2 studies in intermediate-grade non-muscle invasive bladder cancer (IR-NMIBC) (1H:26) and in achondroplasia (ACH) (2H:26). TYRA also recently announced plans to initiate a Ph 2 study in upper tract urothelial carcinoma (UTUC) in 2026, which we believe is an underappreciated opportunity and a potential fast-to-market strategy. We are increasing our price target to $37 (from $30) as we realign our model away from the metastatic UC setting to UTUC, and update timelines based on recent guidance.
0 · Reply
Quantumup
Quantumup Dec. 4 at 1:26 PM
Goldman Sachs🏁 $TYRA at an Early-Stage Biotech rating. $BBIO $JNJ $INCY $OTSKY Here's what Goldman Sachs had to say in its initiation report: https://x.com/Quantumup1/status/1996570205779099845?s=20
0 · Reply
destinyb5
destinyb5 Dec. 3 at 6:18 PM
$TYRA $SPY
0 · Reply
PaulLaurent
PaulLaurent Nov. 24 at 8:06 AM
🔥 Short Squeeze Radar (ORTEX scores) — This Week $TYRA – 80,60/100. Elevated setup; watch borrow fees/locates and VWAP/pivot reclaims. $EPSM – 80,78/100. Recent runner profile; look for higher-low structure and volume persistence. $QMMM – 68,05/100. Mid-tier; needs strong volume and a clean reclaim to trigger. $NVRI – 63,11/100. Lower-tier risk; likely needs a fresh catalyst plus tight borrow to squeeze. $SGML – 73,84/100. Theme-sensitive; monitor borrow dynamics and headline flow for acceleration. Plan: Focus on VWAP/pivot reclaims, scale into strength on clean squeezes, and keep stops tight if borrow loosens or momentum stalls.
1 · Reply
Latest News on TYRA
Tyra Biosciences Strengthens Leadership Team with Appointments of Bhavesh Ashar as Chief Operating Officer and Heather Faulds as Chief Regulatory Officer

Dec 1, 2025, 8:00 AM EST - 6 weeks ago

Tyra Biosciences Strengthens Leadership Team with Appointments of Bhavesh Ashar as Chief Operating Officer and Heather Faulds as Chief Regulatory Officer

Tyra Biosciences Announces Participation at Upcoming Investor Events

Nov 12, 2025, 4:05 PM EST - 2 months ago

Tyra Biosciences Announces Participation at Upcoming Investor Events

Tyra Biosciences Reports Third Quarter 2025 Financial Results and Highlights

Nov 5, 2025, 4:05 PM EST - 2 months ago

Tyra Biosciences Reports Third Quarter 2025 Financial Results and Highlights

Tyra Biosciences Announces First Child Dosed in BEACH301, its Phase 2 Study for Dabogratinib (TYRA-300) in Pediatric Achondroplasia

Aug 21, 2025, 8:00 AM EDT - 5 months ago

Tyra Biosciences Announces First Child Dosed in BEACH301, its Phase 2 Study for Dabogratinib (TYRA-300) in Pediatric Achondroplasia

Tyra Biosciences Reports Second Quarter 2025 Financial Results and Highlights

Aug 14, 2025, 4:05 PM EDT - 5 months ago

Tyra Biosciences Reports Second Quarter 2025 Financial Results and Highlights

Tyra Biosciences Announces Fireside Chat on Achondroplasia and Growth Disorders at UBS Biotech Management Live Call Series

Jul 21, 2025, 4:05 PM EDT - 6 months ago

Tyra Biosciences Announces Fireside Chat on Achondroplasia and Growth Disorders at UBS Biotech Management Live Call Series

Tyra Biosciences Announces Late-Breaking Poster Presentation on TYRA-300 Preclinical Results at ENDO 2025

Jul 8, 2025, 4:05 PM EDT - 6 months ago

Tyra Biosciences Announces Late-Breaking Poster Presentation on TYRA-300 Preclinical Results at ENDO 2025

Tyra Biosciences Doses First Patient in Phase 2 Study of TYRA-300 in Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302)

Jun 30, 2025, 8:00 AM EDT - 7 months ago

Tyra Biosciences Doses First Patient in Phase 2 Study of TYRA-300 in Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302)

Tyra Biosciences to Participate at Upcoming Investor Conferences

May 12, 2025, 4:05 PM EDT - 8 months ago

Tyra Biosciences to Participate at Upcoming Investor Conferences

Tyra Biosciences Reports First Quarter 2025 Financial Results and Highlights

May 8, 2025, 4:05 PM EDT - 8 months ago

Tyra Biosciences Reports First Quarter 2025 Financial Results and Highlights

Tyra Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights

Mar 27, 2025, 4:05 PM EDT - 10 months ago

Tyra Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights

Tyra Biosciences to Present at Upcoming Investor Conferences

Feb 11, 2025, 4:05 PM EST - 1 year ago

Tyra Biosciences to Present at Upcoming Investor Conferences

Tyra Biosciences Announces Poster Presentations at 2025 ASCO Gastrointestinal Cancers Symposium

Jan 22, 2025, 8:00 AM EST - 1 year ago

Tyra Biosciences Announces Poster Presentations at 2025 ASCO Gastrointestinal Cancers Symposium

Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Non-Muscle Invasive Bladder Cancer (SURF302)

Jan 10, 2025, 8:00 AM EST - 1 year ago

Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Non-Muscle Invasive Bladder Cancer (SURF302)

Tyra Biosciences Reports Third Quarter 2024 Financial Results and Highlights

Nov 7, 2024, 4:05 PM EST - 1 year ago

Tyra Biosciences Reports Third Quarter 2024 Financial Results and Highlights

Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Pediatric Achondroplasia (BEACH301)

Oct 28, 2024, 7:00 AM EDT - 1 year ago

Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Pediatric Achondroplasia (BEACH301)

Why Is Cancer-Focused Tyra Biosciences Stock Falling On Friday?

Oct 25, 2024, 11:34 AM EDT - 1 year ago

Why Is Cancer-Focused Tyra Biosciences Stock Falling On Friday?

Tyra Biosciences Reports Interim Clinical Proof-of-Concept Data for TYRA-300, an Investigational Oral FGFR3-Selective Inhibitor, in Phase 1/2 SURF301 Study in Patients with Metastatic Urothelial Cancer (mUC)

Oct 24, 2024, 6:21 PM EDT - 1 year ago

Tyra Biosciences Reports Interim Clinical Proof-of-Concept Data for TYRA-300, an Investigational Oral FGFR3-Selective Inhibitor, in Phase 1/2 SURF301 Study in Patients with Metastatic Urothelial Cancer (mUC)

Tyra Biosciences to Host Conference Call on Interim Clinical Data of TYRA-300 from SURF301 Phase 1/2 Study on October 25, 2024, at 8am ET

Oct 23, 2024, 4:05 PM EDT - 1 year ago

Tyra Biosciences to Host Conference Call on Interim Clinical Data of TYRA-300 from SURF301 Phase 1/2 Study on October 25, 2024, at 8am ET

Tyra Biosciences: Upcoming FGFR3 Inhibitor Data Is A Major Inflection Point

Oct 21, 2024, 7:55 AM EDT - 1 year ago

Tyra Biosciences: Upcoming FGFR3 Inhibitor Data Is A Major Inflection Point

BofA Upgrades Tyra Biosciences As Investors Focus On Preclinical Data Amid High Benchmarks Set By Johnson & Johnson's Drug

Oct 18, 2024, 2:34 PM EDT - 1 year ago

BofA Upgrades Tyra Biosciences As Investors Focus On Preclinical Data Amid High Benchmarks Set By Johnson & Johnson's Drug

This Datadog Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday

Oct 18, 2024, 9:51 AM EDT - 1 year ago

This Datadog Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday

DDOG ACI ECL VCTR

Tyra Biosciences Announces Late-Breaking Oral Presentation on Preliminary Safety and Anti-Tumor Activity of TYRA-300 from SURF301 at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2024)

Oct 11, 2024, 8:00 AM EDT - 1 year ago

Tyra Biosciences Announces Late-Breaking Oral Presentation on Preliminary Safety and Anti-Tumor Activity of TYRA-300 from SURF301 at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2024)

The Schall Law Firm Is Looking Into Tyra Biosciences Inc For Possibly Violating Securities Laws And The Firm Seeks Shareholder Participation

Sep 12, 2024, 11:00 AM EDT - 1 year ago

The Schall Law Firm Is Looking Into Tyra Biosciences Inc For Possibly Violating Securities Laws And The Firm Seeks Shareholder Participation

Tyra Biosciences to Present at the 2024 Cantor Global Healthcare Conference

Sep 11, 2024, 4:05 PM EDT - 1 year ago

Tyra Biosciences to Present at the 2024 Cantor Global Healthcare Conference

Tyra Biosciences, Inc. May Have Defrauded Shareholders And Impacted Individuals Are Invited To Join The Schall Law Firm's Investigation

Sep 11, 2024, 4:00 AM EDT - 1 year ago

Tyra Biosciences, Inc. May Have Defrauded Shareholders And Impacted Individuals Are Invited To Join The Schall Law Firm's Investigation

Tyra Biosciences Appoints Doug Warner, M.D., as Chief Medical Officer

Sep 10, 2024, 4:05 PM EDT - 1 year ago

Tyra Biosciences Appoints Doug Warner, M.D., as Chief Medical Officer

Tyra Biosciences, Inc. Is Being Investigated For Possible Securities Fraud And The Schall Law Firm Wants Shareholders To Participate

Sep 9, 2024, 11:00 AM EDT - 1 year ago

Tyra Biosciences, Inc. Is Being Investigated For Possible Securities Fraud And The Schall Law Firm Wants Shareholders To Participate

Fraudulent Practices May Have Been Committed By Tyra Biosciences Inc And Affected Investors Are Urged To Reach Out To The Schall Law Firm

Sep 7, 2024, 11:00 AM EDT - 1 year ago

Fraudulent Practices May Have Been Committed By Tyra Biosciences Inc And Affected Investors Are Urged To Reach Out To The Schall Law Firm

Investors Are Invited By The Schall Law Firm To Partake In An Inquiry In Tyra Biosciences, Inc's Possible Violations Of Securities Regulations

Sep 6, 2024, 11:00 AM EDT - 1 year ago

Investors Are Invited By The Schall Law Firm To Partake In An Inquiry In Tyra Biosciences, Inc's Possible Violations Of Securities Regulations

Tyra Biosciences, Inc. Is Being Looked Into For Acting Wrongfully And The Schall Law Firm Has Launched An Investigation That Shareholders Can Join

Sep 5, 2024, 11:00 AM EDT - 1 year ago

Tyra Biosciences, Inc. Is Being Looked Into For Acting Wrongfully And The Schall Law Firm Has Launched An Investigation That Shareholders Can Join

The Schall Law Firm Is Looking Into Tyra Biosciences Inc. For Possible Securities Related Infractions And Stockholders Can Assist

Sep 4, 2024, 11:00 AM EDT - 1 year ago

The Schall Law Firm Is Looking Into Tyra Biosciences Inc. For Possible Securities Related Infractions And Stockholders Can Assist

Tyra Biosciences Inc Stockholders Can Partake In An Inquiry Into Whether The Company Defrauded The Public

Sep 2, 2024, 11:00 AM EDT - 1 year ago

Tyra Biosciences Inc Stockholders Can Partake In An Inquiry Into Whether The Company Defrauded The Public

Attention Investors: The Schall Law Firm Is Looking Into Tyra Biosciences Inc. For Potentially Violating Securities Laws And Investors Can Reach Out

Sep 1, 2024, 11:00 AM EDT - 1 year ago

Attention Investors: The Schall Law Firm Is Looking Into Tyra Biosciences Inc. For Potentially Violating Securities Laws And Investors Can Reach Out

An Inquiry Is Being Made Into Whether Tyra Biosciences Has Defrauded The Public And The Schall Law Firm Wants Shareholders To Help

Aug 31, 2024, 11:00 AM EDT - 1 year ago

An Inquiry Is Being Made Into Whether Tyra Biosciences Has Defrauded The Public And The Schall Law Firm Wants Shareholders To Help

Tyra Biosciences May Have Broken Securities Laws And Impacted Stakeholders Are Urged To Lend A Hand To The Schall Law Firm's Inquiry

Aug 30, 2024, 11:00 AM EDT - 1 year ago

Tyra Biosciences May Have Broken Securities Laws And Impacted Stakeholders Are Urged To Lend A Hand To The Schall Law Firm's Inquiry

The Public Is Encouraged To Reach Out To The Schall Law Firm About An Inquiry Into Tyra Biosciences Inc.'s Potentially Fraudulent Actions

Aug 29, 2024, 11:00 AM EDT - 1 year ago

The Public Is Encouraged To Reach Out To The Schall Law Firm About An Inquiry Into Tyra Biosciences Inc.'s Potentially Fraudulent Actions

The Schall Law Firm Invites Investors In Tyra Biosciences Inc To Partake In An Investigation Into Securities Fraud

Aug 28, 2024, 11:00 AM EDT - 1 year ago

The Schall Law Firm Invites Investors In Tyra Biosciences Inc To Partake In An Investigation Into Securities Fraud

An Inquiry Has Been Opened Into Tyra Biosciences Inc's Possible Securities Related Impropriety And Impacted Stakeholders Should Join

Aug 27, 2024, 11:00 AM EDT - 1 year ago

An Inquiry Has Been Opened Into Tyra Biosciences Inc's Possible Securities Related Impropriety And Impacted Stakeholders Should Join

The Schall Law Firm Is Inquiring Into Tyra Biosciences Inc.'s Potential Securities Fraud And Affected Investors Can Participate

Aug 25, 2024, 11:00 AM EDT - 1 year ago

The Schall Law Firm Is Inquiring Into Tyra Biosciences Inc.'s Potential Securities Fraud And Affected Investors Can Participate

Tyra Biosciences Inc. Shareholders Can Reach Out To The Schall Law Firm About An Investigation Into Possible Breaches Of Securities Laws

Aug 24, 2024, 11:00 AM EDT - 1 year ago

Tyra Biosciences Inc. Shareholders Can Reach Out To The Schall Law Firm About An Investigation Into Possible Breaches Of Securities Laws

Investors With Losses In Tyra Biosciences Inc. Are Urged To Join An Inquiry Into Possible Securities Fraud With The Schall Law Firm

Aug 23, 2024, 11:00 AM EDT - 1 year ago

Investors With Losses In Tyra Biosciences Inc. Are Urged To Join An Inquiry Into Possible Securities Fraud With The Schall Law Firm

GreenPhantom
GreenPhantom Jan. 5 at 1:34 AM
$TYRA Tyra's pipeline is focused on precision medicine and developing drugs that target specific cancer mutations.
0 · Reply
GreenPhantom
GreenPhantom Jan. 5 at 1:33 AM
$TYRA
0 · Reply
GreenPhantom
GreenPhantom Jan. 5 at 1:32 AM
$TYRA Strong Scientific Foundation and Experienced Management
0 · Reply
TradeBalanceT
TradeBalanceT Dec. 25 at 1:11 PM
$TYRA Capital stewardship is becoming the defining attribute for how this story is priced. The market is increasingly intolerant of delays that stretch credibility. Without proof, upside scenarios remain hypothetical and heavily discounted. The market will respond to evidence, not speculation.
0 · Reply
anachartanalyst
anachartanalyst Dec. 16 at 8:02 PM
$TYRA https://anachart.com/wp-content/uploads/ana_temp/1765915319_soc-img.jpg
0 · Reply
JarvisFlow
JarvisFlow Dec. 16 at 12:36 PM
Wedbush updates rating for Tyra Biosciences ( $TYRA ) to Outperform, target set at 30 → 37.
0 · Reply
Quantumup
Quantumup Dec. 16 at 12:14 PM
Wedbush Added $TYRA to their Best Idea List while⬆️the PT to $37 from $30 and reiterating at an Outperform rating. $URGN $JNJ $BBIO $ASND SNY BMRN Wedbush said—We are adding TYRA to the Wedbush Best Ideas List ahead of a busy 2026, with data from two ongoing Ph 2 studies in intermediate-grade non-muscle invasive bladder cancer (IR-NMIBC) (1H:26) and in achondroplasia (ACH) (2H:26). TYRA also recently announced plans to initiate a Ph 2 study in upper tract urothelial carcinoma (UTUC) in 2026, which we believe is an underappreciated opportunity and a potential fast-to-market strategy. We are increasing our price target to $37 (from $30) as we realign our model away from the metastatic UC setting to UTUC, and update timelines based on recent guidance.
0 · Reply
Quantumup
Quantumup Dec. 4 at 1:26 PM
Goldman Sachs🏁 $TYRA at an Early-Stage Biotech rating. $BBIO $JNJ $INCY $OTSKY Here's what Goldman Sachs had to say in its initiation report: https://x.com/Quantumup1/status/1996570205779099845?s=20
0 · Reply
destinyb5
destinyb5 Dec. 3 at 6:18 PM
$TYRA $SPY
0 · Reply
PaulLaurent
PaulLaurent Nov. 24 at 8:06 AM
🔥 Short Squeeze Radar (ORTEX scores) — This Week $TYRA – 80,60/100. Elevated setup; watch borrow fees/locates and VWAP/pivot reclaims. $EPSM – 80,78/100. Recent runner profile; look for higher-low structure and volume persistence. $QMMM – 68,05/100. Mid-tier; needs strong volume and a clean reclaim to trigger. $NVRI – 63,11/100. Lower-tier risk; likely needs a fresh catalyst plus tight borrow to squeeze. $SGML – 73,84/100. Theme-sensitive; monitor borrow dynamics and headline flow for acceleration. Plan: Focus on VWAP/pivot reclaims, scale into strength on clean squeezes, and keep stops tight if borrow loosens or momentum stalls.
1 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Nov. 23 at 9:09 PM
$TWST $TXG $TXT $TYLG 🔥 $TYRA 🔥
0 · Reply
monkfruit
monkfruit Nov. 21 at 4:46 PM
$TYRA Sold for a 51.64% gain. 🤯 This stock way outperformed my expectations. Might keep going up, but I'm happy here. https://stocktwits.com/monkfruit/message/628677685
0 · Reply
StockScanners
StockScanners Nov. 21 at 4:30 AM
$TYRA keep watch if this holds above 20.35
0 · Reply
BioTechHealthX
BioTechHealthX Nov. 21 at 12:14 AM
$TYRA Tyra Biosciences (NASDAQ:TYRA) enters 2026 with $274.9M in cash and multiple Phase 2 readouts, including pivotal data for dabogratinib in achondroplasia and bladder cancer. Learn why investors are watching this FGFR3-focused biotech preparing for its biggest year yet. https://biotechhealthx.com/biotech-news/tyra-biosciences-tyra-the-274-9m-precision-biotech-betting-big-on-fgfr3-breakthroughs-in-2026/
0 · Reply
topstockalerts
topstockalerts Nov. 20 at 8:51 PM
$TYRA let's close strong.. 🏦
0 · Reply
Doozio
Doozio Nov. 20 at 8:05 PM
$TYRA 🐒🍌🧠⏰♾️
0 · Reply
kshonstocks
kshonstocks Nov. 20 at 7:59 PM
$TYRA something right
0 · Reply
topstockalerts
topstockalerts Nov. 20 at 6:35 PM
$TYRA it wants to squeeze higher.. ✅
0 · Reply
monkfruit
monkfruit Nov. 20 at 6:17 PM
$TYRA 😳
0 · Reply
Doozio
Doozio Nov. 20 at 2:41 AM
All the way up YO Roger $TYRA as long as it’s not a faaatch 💣 that’s up it!
0 · Reply
Doozio
Doozio Oct. 15 at 10:34 PM
Chop chop huckleberries $TYRA. It’s 🐒🍌🧠⏰♾️
0 · Reply